A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 154
- 试验地点
- 18
- 主要终点
- Percentage of Participants with Adverse Events (AE)
研究概览
简要总结
This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic fatty liver disease(NAFLD). A maximum of approximately 160 participants will be enrolled across multiple sites in the United States. Participants will be randomly assigned to receive study drug (active BFKB8488A or placebo). The study will consist of a screening period (up to 8 weeks), a 12-week treatment period, and a 6-week follow-up period. Participants may come to clinic for an optional pre-screening visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For T2DM Cohort only:
- •Body mass index (BMI) ≥ 27 kg/m2 and ≤ 40 kg/m
- •A confirmed diagnosis of Type 2 diabetes ≥ 6 months at screening
- •Current stable treatment (at least 3 months) for diabetes
- •Hemoglobin A1c (HbA1c) ≥ 6.8% and ≤ 9.0%.
- •For women of childbearing potential, agreement to remain abstinent or use reliable contraception during treatment period and for at least 42 days after last dose of study drug
- •For men, agreement to remain abstinent or use reliable contraception and agree to refrain from donating sperm
- •For NAFLD cohort only:
- •BMI ≥ 25 kg/m2 and ≤ 40 kg/m2
- •At screening, confirmed liver fat by ultrasound OR calculated Liver Fat ≥ 10% using variables from the NAFLD liver fat score
- •Hepatic steatosis on magnetic resonance imaging (MRI; ≥ 10% average liver proton density fat fraction [PDFF]) prior to randomization.
排除标准
- •Pregnant, lactating, or intending to become pregnant within 42 days after the last dose of study drug is administered
- •Suspected or confirmed diagnosis of Type 1 diabetes
- •Significant cardiac disease
- •Any psychiatric illness that increases the risk of participation in the study
- •History of severe allergic, anaphylactic, or other hypersensitivity reactions, or severe systemic bacterial, fungal, or parasitic infections
- •Poor peripheral venous access
- •Received blood products within 2 months before dosing
- •Donation or loss of blood within 30-56 days prior to study drug administration
- •Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody
- •Liver enzymes greater than acceptable limits
- •History of eating disorders or surgical procedures for weight loss
- •Active participation in a structured weight loss or dietary program
- •Treatment with investigational therapy or exposure to any biological therapy
- •Illicit drug use, marijuana use, or alcohol abuse
- •Current use of more than one pack of cigarettes a day or equivalent nicotine- containing products
- •Any serious medical condition or abnormality in clinical laboratory tests
研究组 & 干预措施
Multiple Ascending Dose BFKB8488A
Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
干预措施: BFKB8488A (Drug)
Placebo
Participants will receive BFKB8488A-matching placebo.
干预措施: Placebo (Other)
结局指标
主要结局
Percentage of Participants with Adverse Events (AE)
时间窗: Up to 18 weeks following first dose administration
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
次要结局
- Serum BFKB8488A Concentration(On multiple days during treatment period and follow-up (up to 18 weeks following first dose administration))
- Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs)(On multiple days during treatment period and follow-up (up 18 weeks following first dose administration))